Streetbeat News

Analyst Ratings

KRTX

Analysts have provided mostly bullish ratings for Karuna Therapeutics (NASDAQ:KRTX) in the last quarter, with an average 12-month price target of $279.18. The average price target has increased by 1.96% over the past month.

Portfolio Pulse from Benzinga Insights

June 01, 2023 | 4:02 pm

ADNT

Over the past 3 months, 4 analysts have published somewhat bullish opinions on Adient (NYSE:ADNT) stock, with an average 12-month price target of $50.25, down 4.29% from the previous average of $52.50.

Portfolio Pulse from Benzinga Insights

June 01, 2023 | 4:01 pm

ECL

In the last 3 months, 8 analysts have offered 12-month price targets for Ecolab (NYSE:ECL), with an average price target of $183.38, up 11.82% from the previous average of $164.00.

Portfolio Pulse from Benzinga Insights

June 01, 2023 | 4:00 pm

CVNA

Carvana Co (NYSE:CVNA) shares are trading higher on Thursday after receiving positive upgrades and revisions from S&P Global Ratings. S&P raised its ratings on several Carvana-sponsored securitizations backed by prime and non-prime auto loans, and lowered its loss assumptions on seven transactions.

Portfolio Pulse from Erica Kollmann

June 01, 2023 | 4:00 pm

VOYA

Citigroup analyst Michael Ward has reiterated a Buy rating on Voya Financial (NYSE:VOYA) but lowered the price target from $90 to $85.

Portfolio Pulse from Benzinga Newsdesk

June 01, 2023 | 3:56 pm

TTD

The Trade Desk (TTD) shares are trading higher after RBC Capital maintained an Outperform rating on the stock and raised its price target from $77 to $85.

Portfolio Pulse from Benzinga Newsdesk

June 01, 2023 | 3:52 pm

PLTR

Palantir Technologies (PLTR) is in the spotlight due to its Q1 earnings beat, collaboration with Ukraine Ministry, and hosting its AI day. However, Bear Cave criticized the company, calling it an AI imposter and accusing it of inflating its financial profile.

Portfolio Pulse from Anusuya Lahiri

June 01, 2023 | 3:51 pm

AI

C3.ai reported Q4 earnings with a revenue of $72.4 million, beating estimates. The company posted a loss of 13 cents per share, better than the expected loss of 17 cents. Analysts from Wedbush, JMP Securities, and Needham provided their insights and updated price targets.

Portfolio Pulse from AJ Fabino

June 01, 2023 | 3:49 pm

ARCT

HC Wainwright & Co. analyst Ed Arce reiterated a Buy rating on Arcturus Therapeutics (NASDAQ:ARCT) and maintained a $51 price target.

Portfolio Pulse from Benzinga Newsdesk

June 01, 2023 | 3:40 pm

JKHY

Bank of America Securities analyst Jason Kupferberg initiates coverage on Jack Henry & Associates (NASDAQ:JKHY) with a Neutral rating and a price target of $156.

Portfolio Pulse from richadhand@benzinga.com

June 01, 2023 | 3:15 pm